Apogem Capital’s LENZ Therapeutics LENZ Stock Holding History

Apogem Capital’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3,619	Closed	-$80K	–	120
2022 Q3	$80K	Buy	+3,619	New	+$86.2K	0.08%	133

Other funds holding LENZ

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Apogem Capital's LENZ Position: Q4 2022 in Review

Apogem Capital sold out of LENZ Therapeutics (LENZ) in Q4 2022, closing a stake of 3,619 shares — an estimated $80K sold.

Apogem Capital first reported a position in LENZ in Q3 2022 and held it in 1 quarter. The position peaked at $80K in Q3 2022. 66 funds tracked by Wall St. Rank hold LENZ as of Q4 2022.

Apogem Capital reported no remaining LENZ Therapeutics position as of Q4 2022 after selling out during the quarter.
Apogem Capital sold 3,619 LENZ Therapeutics shares in Q4 2022, an estimated $80K.
Apogem Capital first reported a position in LENZ Therapeutics in Q3 2022 and held it in 1 quarter.
Apogem Capital's LENZ Therapeutics position peaked at $80K in Q3 2022.
66 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q4 2022.

Based on Apogem Capital's 13F filing for Q4 2022, filed 13 Feb 2023.